Stay updated on Pembrolizumab vs Brentuximab in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Brentuximab in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab vs Brentuximab in Hodgkin Lymphoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedUpdate timestamps were added/adjusted on the page, reflecting recent edits to the record. No changes to the study design, eligibility criteria, or outcomes were observed.SummaryDifference0.3%

- Check17 days agoChange DetectedRevision: v3.4.2 was added; notices for Revision: v3.4.1 and the government funding status alert were removed.SummaryDifference0.5%

- Check25 days agoChange DetectedAdded a government funding lapse notice with status update for the NIH Clinical Center, and updated the site revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check32 days agoChange DetectedThe page now displays the glossary toggle, updates QA-related labels with capitalization changes (Last Update Submitted that Met QC Criteria / No FEAR Act Data), and upgrades the revision to v3.4.0.SummaryDifference0.2%

- Check46 days agoChange DetectedThe page footer revision updated from v3.3.3 to v3.3.4; no changes to study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check60 days agoChange DetectedLabel for the update timestamp changed from 'Last Update Posted' to 'Last Update Posted (Estimated)'. This is a minor labeling change to the update date display and does not alter study information; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab vs Brentuximab in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Brentuximab in Hodgkin Lymphoma Clinical Trial page.